Relationship between circulating testosterone and emotional behavior in rats

The experiment was aimed at investigating the relationship between reduced circulating/endogenous testosterone occasioned by orchiectomy and emotional behavior using the open field test. Eighteen male Wistar rats were randomly selected and classified into two groups: orchiectomized and nonorchiectomized. Orchiectomy was carried out by simple sham surgery. After recovery from orchiectomy, plasma testosterone was determined in both groups after which each animal was observed in the open-field for neurobehavioral activities. The result showed a significant (p <0.05) reduction in plasma testosterone concentration as well as the frequencies of novelty-induced neurobehaviors scored in the open field arena in the orchiectomized group when compared with the nonorchiectomized group. Results indicated that a reduction in circulating testosterone exerts behavioral deficits in orchiectomized animals in the form of fear imposed by exposure to a novel environment resulting in fewer activities. This observation was confirmed by the presence of testosterone receptors in specific brain areas associated with behavioral modulation. We therefore conclude that circulating testosterone could be one of the endogenous mechanisms responsible for coping with fear induced by exposure to a novel environment.

Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica / Repercusión de un subsidio del Fondo Nacional de Salud en la hormonoterapia para el cáncer de próstata en Jamaica

OBJECTIVE: To compare the proportion of patients choosing surgical versus medical castration to treat prostate cancer, before and after the National Health Fund (NHF) of Jamaica began to subsidize hormone therapy. METHODS: A retrospective review was performed at the University Hospital of the West Indies (UHWI), Jamaica. The pathology database at UHWI was searched to identify patients who had prostate biopsies between January 2000 and December 2007. These were combined with records of biopsies at external institutions. Medical records of all patients with positive prostate biopsies were reviewed to determine if they had received androgen deprivation therapy (ADT). Patients were classified as having had surgical castration (bilateral orchiectomy) or medical castration. Chi-square statistics were used to determine the difference in proportions between those choosing medical versus surgical castration before and after March 2005, when the NHF began offering subsidies for ADT drugs. RESULTS: Of the 1 529 prostate biopsies performed during the study period, 680 (44.0 percent) cases of prostate cancer were diagnosed. Of these, 458 patients underwent ADT and had complete records available for analysis. The mean patient age was 72 years. During the entire study period, surgical castration was performed in 265 patients (58.0 percent) and medical castration in 193 (42.0 percent). A greater proportion of orchiectomies were performed before March 2005, rather than after (P < 0.001). Estrogens were the most common method of medical castration used before the NHF subsidy became available (62.0 percent); while luteinizing hormone-releasing hormone analogues (38.0 percent) and antiandrogens (36.5 percent) were most often chosen afterwards. CONCLUSIONS: Surgical castration was more common than medical castration before March 2005. After the NHF began to subsidize the cost of drugs for hormone therapy, medical castration was chosen more often. Increased access to drugs for hormone therapy has changed treatment patterns in Jamaica.

OBJETIVO: Comparar la proporción de pacientes que eligen la castración quirúrgica frente a la castración farmacológica para tratar el cáncer de próstata, antes y después de la creación de un subsidio del Fondo Nacional de Salud (NHF, por sus siglas en inglés) de Jamaica destinado a cubrir los costos de la hormonoterapia. MÉTODOS: Se llevó a cabo un examen retrospectivo en el Hospital Universitario de las Indias Occidentales, Jamaica. Se efectuó una búsqueda en la base de datos de enfermedades de dicho hospital para identificar a los pacientes a quienes se les había practicado una biopsia de próstata entre enero del 2000 y diciembre del 2007. Los datos se combinaron con los registros de biopsias llevadas a cabo en instituciones externas. Se estudiaron las historias clínicas de todos los pacientes con resultados positivos en la biopsia de próstata para determinar si habían recibido tratamiento de supresión androgénica. Los pacientes se clasificaron en dos grupos, según se hubieran tratado mediante castración quirúrgica (orquiectomía bilateral) o farmacológica. Se usó la prueba de la ji al cuadrado para determinar la diferencia en las proporciones entre los pacientes que escogieron la castración quirúrgica y los que escogieron la opción farmacológica antes y después de marzo del 2005, la fecha en la que el NHF empezó a subsidiar los medicamentos de supresión androgénica. RESULTADOS: Entre las 1 529 biopsias de próstata realizadas durante el período de estudio, hubo 680 (44,0 por ciento) casos con diagnóstico de cáncer de próstata. De estos, 458 pacientes habían recibido tratamiento de supresión androgénica y se disponía de sus registros completos para el análisis. La edad media de los pacientes fue de 72 años. Durante el período de estudio, se les practicó castración quirúrgica a 265 pacientes (58,0 por ciento) y castración farmacológica a 193 (42,0 por ciento). La proporción de orquiectomías fue mayor antes de marzo del 2005 que después de esa fecha (P < 0,001). Los estrógenos fueron el método de castración farmacológica más común antes de la creación del subsidio del NHF (62,0 por ciento); a partir de ese momento se eligieron con mayor frecuencia los análogos de la hormona liberadora de la hormona luteinizante (38,0 por ciento) y los antiandrógenos (36,5 por ciento). CONCLUSIONES: La castración quirúrgica era más común que la castración farmacológica antes de marzo del 2005. Después de que el NHF empezó a subsidiar el costo de los medicamentos para el tratamiento hormonal, la opción escogida con más frecuencia fue la castración farmacológica. El mayor acceso a los medicamentos usados en la hormonoterapia ha cambiado los patrones de tratamiento del cáncer de próstata en Jamaica.

Orquiectomia total versus orquiectomia subcapsular para tratamento de câncer de próstata metastático: comparaçäo dos níveis pré e pós operatórios de testosterona total e PSA / Total versus subcapsular orchiectomy for treatment of advanced prostatic carcinoma: comparison of serum testosterone and PSA levels

No momento do diagnóstico do câncer prostático, grande parte dos pacientes já tem doença disseminada. O tratamento com deprivaçäo androgênica é o mais indicado nesses casos, sendo a orquiectomia um método muito eficaz, que porém pode trazer consequências psicológicas. Alguns autores defendem a orquiectomia total (OT) com o argumento de que células de Leydig podem permanecer na albugínea quando a orquiectomia subcapsular (OS) é realizada, podendo comprometer a deprivaçäo hormonal. Com o objetivo de comparar a OT com a OS foi realizado um estudo com 58 pacientes com câncer de próstata estádio-D2, divididos em 2 grupos randomizados (grupo A: pacientes submetidos a OT e grupo B: 30 pacientes com OS). Dosou-se a testosterona total e o PSA imediatamente antes da cirurgia e 6 meses após. Utilizou-se o teste "t" de student para comparaçäo entre os grupos, näo sendo encontrada diferença entre eles. Conclui-se que as duas técnicas säo semelhantes sendo que a OS tem a vantagem de diminuir os traumas psicológicos e diminuir custos com a colocaçäo de próteses